NEW YORK, Nov. 07, 2017 /PRNewswire/ -- If you want a Stock Review on MDCO, MNTA, DPLO, or ZTS then come …
A month has gone by since the last earnings report for Momenta Pharmaceuticals, Inc. MNTA. Shares have lost about 9.6% in that time frame, underperforming the market. Will the recent negative trend continue leading up to the stock’s …
Yahoo!8mon
Shares of Momenta Pharmaceuticals Inc. MNTA were down 12.6% after the company reported disappointing ... However, revenues were down 17.3% from the year-ago quarter. Momenta’s stock has decreased 15.1% year to date compared …
Momenta Pharmaceuticals Inc. MNTA, +4.41% shares jumped 9.7% in pre-market trade Tuesday after the company said a phase 3 clinical trial for its Humira biosimilar met its primary endpoint. The drug, M923, is being developed with Shire's …
Bank of America analyst Sumant S. Kulkarni wrote, "While fundamentals remain similar and we are not changing our …
The stock has increased 26 percent in the last 12 months. This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MNTA
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and Mylan N.V. (Nasdaq: MYL) announced that dosing has begun in a Phase 1 study to compare the …